Investigating the Effect of Ivabradine Drug on Controlling the Ventricular Response in Atrial Fibrillation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240207060933N1

Enrollment

Registered

2024-02-14

Start date

2024-03-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Atrial fibrillation and flutter

Interventions

Intervention group: One month's use of ivabradine at a dose of 5 mg twice a day.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with permanent or persistent AF Heart rate greater than 100 beats per minute at rest.

Exclusion criteria

Exclusion criteria: Age less than 18 years Pregnant women Women who breastfeed their children Patients with acute liver and kidney failure Lack of consent to start or continue the treatment process Patients with uncontrolled blood pressure

Design outcomes

Primary

Measure	Time frame
Ventricular Response. Timepoint: one month. Method of measurement: ECG Holter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Payami

Ahvaz University of Medical Sciences

Payami-b@ajums.ac.ir+98 61 3222 6721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026